BCL2 and acute myeloid leukemia: In yet another phase 1 study in elderly AML patients administered with oblimersen and cytarabine, or daunorubicin investigators found that those patients with a complete remission (48%) experienced decreased Bcl-2 mRNA and protein levels in bone marrow samples after 72 h of drug infusion and prior to chemotherapy whereas, increased Bcl-2 was seen in the non-responders (26).